In February, NZ rolled out new rules promising easier access to ADHD treatment. Today, gaps in training, cost and access show why the reform was only a first step.
Articles on ADHD medication
Displaying all articles
Yes, telehealth has improved access for people seeking ADHD treatment. But a new study suggests it’s also a money spinner.
While children living in poorer areas used to have the highest rates of ADHD prescriptions, this has flipped.
Some people have to call around pharmacies to get their script filled, others change to different medications. And the shortage is expected to continue.
ADHD is the most diagnosed childhood neurological disorder, but there have been inconsistencies around who is diagnosed and prescribed medication. New prescribing guidelines aim to change this.
Autism and ADHD frequently overlap and the combination can create internal conflict and unmet needs.
The study found people with ADHD who took medication had a lower risk of dying from unnatural causes than those with ADHD who were not taking medication.
Fully 97% of people with ADHD in the UK have had difficulty getting their medication due to supply issues.
Most people stop taking ADHD medication within two years of starting it. The hope is that they’ve developed successful strategies to manage the condition in that time.
Experts examine the five questions they commonly hear from women and girls about their hormones and ADHD symptoms.
The COVID-19 pandemic may have played a considerable role in the uptick of adults being treated for ADHD. But more data is needed to determine whether the trends will continue.
Noradrenergic drugs are already used to treat a variety of conditions, including ADHD and depression.
ADHD diagnoses are on the rise, a trend that might in part be driven by overdiagnosis. A new study finds that white children are especially likely to be overdiagnosed and overtreated for ADHD.
Handling adult ADHD is difficult, but today, there are more evidence-based interventions than ever.
Top contributors
-
Partner, Government & Public Sector, Providence / Honorary Fellow, Australian National University
-
Psychologist and Research Associate in the Department of Paediatrics, Monash University
-
Director, Institute for Social and Health Equity, University at Albany, State University of New York
-
Senior Lecturer, Brain Mind Centre Nepean, University of Sydney
-
Professor in Cognitive Neuroscience, Director of Research, Turner Institute for Brain and Mental Health, Monash University
-
Neuroscience PhD candidate, Cardiff University
-
Lecturer in Clinical Pharmacy, Aston University
-
Professor of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington
-
Professor of Psychology, University of Richmond
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, Social Psychiatry and Epidemiology Research Unit, School of Medicine and Psychology, Australian National University
-
Associate Professor, Research School of Finance, Actuarial Studies and Statistics, Australian National University
-
Professor of Psychiatry, Flinders University
-
Associate Professor, Faculty of Business, Government and Law, University of Canberra
-
Visiting Fellow, National Centre for Health Workforce Studies, Australian National University